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Abstract
Background: Non-neutralising antibodies to the envelope glycoprotein are elicited during acute HIV-1 infection
and are abundant throughout the course of disease progression. Although these antibodies appear to have
negligible effects on HIV-1 infection when assayed in standard neutralisation assays, they have the potential to
exert either inhibitory or enhancing effects through interactions with complement and/or Fc receptors. Here we
report that non-neutralising antibodies produced early in response to HIV-1 infection can enhance viral infectivity.
Results: We investigated this complement-mediated antibody-dependent enhancement (C’-ADE) of early HIV
infection by carrying out longitudinal studies with primary viruses and autologous sera derived sequentially from
recently infected individuals, using a T cell line naturally expressing the complement receptor 2 (CR2; CD21). The
C’-ADE was consistently observed and in some cases achieved infection-enhancing levels of greater than 350-fold,
converting a low-level infection to a highly destructive one. C’-ADE activity declined as a neutralising response to
the early virus emerged, but later virus isolates that had escaped the neutralising response demonstrated an
increased capacity for enhanced infection by autologous antibodies. Moreover, sera with autologous enhancing
activity were capable of C’ADE of heterologous viral isolates, suggesting the targeting of conserved epitopes on
the envelope glycoprotein. Ectopic expression of CR2 on cell lines expressing HIV-1 receptors was sufficient to
render them sensitive to C’ADE.
Conclusions: Taken together, these results suggest that non-neutralising antibodies to the HIV-1 envelope that
arise during acute infection are not ‘passive’, but in concert with complement and complement receptors may
have consequences for HIV-1 dissemination and pathogenesis.
Background
Many antibodies produced by HIV-1-infected individuals
bind to the viral envelope glycoprotein, yet fail to neu-
tralise the virus. These non-neutralising responses are
usually considered ‘silent’ because they have little effect
on HIV-1 infectivity in traditional neutralisation assays.
However, antibodies also have other effector functions,
including their ability to activate complement, a cascade
of serum proteins that can be deposited on the virion
membrane. Complement activation can lead to both
viral inactivation and enhanced infection, with the latter
depending on cellular expression of receptors for com-
plement components (CRs). We have examined the
effects of complement on antibodies and viruses from
patients with acute HIV-1 infection using cell lines with
a CR (CR2). We show that, far from being ‘silent’, anti-
bodies present during acute infection can enhance viral
infectivity by up to several hundred-fold, primarily by
stabilising interactions between the virus and the cell.
Furthermore, viruses that escape from a neutralising
response remain susceptible to enhancement. Since
many immune cells that HIV-1 infects or interacts with
express CRs, antibody-complement interactions may
play an important role in the pathogenesis of HIV/
AIDS, and could be detrimental to host control of HIV-
* Correspondence: m.aasa-chapman@ucl.ac.uk
1MRC/UCL Centre for Medical Molecular Virology, Division of Infection and
Immunity, University College London, 46 Cleveland Street, London W1T 4JF,
UK
Full list of author information is available at the end of the article
Willey et al. Retrovirology 2011, 8:16
http://www.retrovirology.com/content/8/1/16
© 2011 Willey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
1 as well as a consideration in the evaluation of envel-
ope-based vaccines.
Introduction
HIV envelope-specific antibodies can be detected in the
blood of infected individuals within a few weeks of
infection [1,2]. In contrast, the development of a neutra-
lising antibody response takes several months, with the
timing and potency varying substantially between indivi-
duals [1,3-8]. Following the development of neutralising
antibodies the virus rapidly and repeatedly escapes the
induced response, so that the majority of virus is weakly,
if at all, neutralised by contemporaneous antibodies
[4,5,9,10]. Thus, in early stages of infection prior to the
emergence of a neutralising response, non-neutralising
antibodies predominate; at subsequent stages of infec-
tion, rapid escape by the virus ensures a continuing
abundance of non-neutralising antibodies in the infected
individual [11].
Despite the fact that non-neutralising antibodies do
not directly affect viral infectivity, some of them are still
able to bind to envelope proteins on the viral surface
[12]. Both neutralising and non-neutralising antibodies
bound to the viral surface can activate complement or
bind directly to Fc receptors (FcRs) [11]. HIV can also
activate complement in the absence of antibodies
through direct interactions between the envelope pro-
teins gp41 and gp120, and complement cascade compo-
nents C1q and MBL [13-17], while bound antibodies
amplify complement activation and the deposition of
complement fragments on the viral surface [18-20]. In
both the presence and absence of antibody, comple-
ment-coated virions can then interact with complement
receptors (CRs) that bind C3 fragments or C1q [21].
Interactions between antibodies and FcRs, complement
and CRs, and their downstream consequences, can have
diverse effects on virus replication, but are largely
missed in neutralisation assays due to the absence of
complement in the system and lack of CRs/FcRs on tar-
get or bystander cells. In recent years, a number of anti-
body effector functions have been observed in early HIV
infection, including antibody-dependent cell-mediated
virus inhibition (ADCVI; [22,23]), and activation of the
complement cascade [6,24,25]. Antibody-effector func-
tions have been reported to both increase and compro-
mise the efficacy of neutralising antibodies, and in the
case of non-neutralising antibodies or sub-neutralising
concentrations of neutralising antibodies, inhibit or
enhance HIV infectivity [11].
The effect of complement, particularly, appears to be a
double-edged sword. Inactivation through opsonisation
and lysis have been reported [6,24,26,27], yet when CRs
are present on the target cell, antibodies and comple-
ment can enhance viral infectivity [28-31]. The factors
that determine the outcome of such interactions are of
importance to vaccine studies as they may make the dif-
ference between a preventative and harmful vaccine
candidate.
Enhanced infection of a virus opsonised with comple-
ment and antibodies via CRs on the target cell is termed
complement-mediated antibody-dependent enhancement
(C’-ADE). C’-ADE of HIV has been previously well-
characterised [30-34], but predominantly using X4-tro-
pic T cell line-adapted (TCLA) strains of HIV, and
never, to our knowledge, using primary isolates and
paired autologous antibodies from infected individuals.
Enhancement of HIV by complement alone has also
been reported, and this effect has been observed on pri-
mary cells and with primary strains of HIV [35-38]. Few
of these studies demonstrate greater than 10-fold
increases of viral infectivity, but given the long time-
course of HIV infection this is considered sufficient to
have a significant impact on viral dynamics. CRs so far
implicated in C’-ADE of HIV include CR2 [28,39], CR3
[29] and C1qR [39], with C’-ADE via CR2 most fre-
quently reported. Mechanistically, C’-ADE could occur
by increasing physical attachments between the virus
and the target cell, or through CR2-mediated signalling
events leading to enhanced infection via an alternative
route of entry, enhanced viral replication, or suppression
of intracellular antiviral responses [40]. Current evidence
favours increased attachment to the target cell [41] lead-
ing to enhanced virus entry [42].
Enhancing antibodies have been detected in vitro to a
wide range of viruses [33,40,43], and have been linked
to increased pathogenesis in dengue [44-47], Murray
Valley encephalitis [48], respiratory syncytial [49], ebola
[50] and measles [51] virus infections, and increased
cross-placental transmission of CMV [52]. Upon viral
challenge following vaccination, enhanced acquisition of
infection or accelerated disease progression compared to
placebo controls have been observed for the lentiviruses
FIV [53-57], SIV [58,59], and EIAV [60,61]. Enhancing
antibodies specific for the virus envelope proteins have
been suggested, but not unequivocally proven, to play a
role in vaccine-induced disease enhancement, with
clearest evidence for antibody involvement coming from
passive plasma transfer studies [55].
Here, we report that non-neutralising antibodies pro-
duced early in response to HIV infection can enhance
viral infectivity. We investigated a role for enhancing
antibodies in early HIV infection by carrying out longi-
tudinal studies with primary viruses and autologous sera
derived sequentially from recently infected individuals,
using a T cell line naturally expressing CR2. We found
that C’-ADE was consistent and dramatic, in some cases
achieving infection-enhancing levels of greater than 350-
fold. C’-ADE declined as a neutralising response to the
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early virus emerged, but later virus isolates that had
escaped the neutralising response demonstrated an
increased capacity for enhanced infection by autologous
antibodies. The mechanism of enhancement was investi-
gated by constructing cell lines expressing CR2 (CD21)
or a mutant CR2 lacking a cytoplasmic tail. High-level
C’-ADE occurred through both receptors, indicative of
increased attachment to the target cell being the princi-
pal mechanism.
Results
A model system for studying C’-ADE
Previous C’-ADE studies have been restricted by the target
cell used. Commonly used T cell lines, such as MT-2, do
not support infection by clinically relevant R5 tropic pri-
mary isolates, whereas assays performed on primary cells
have the inherent problem of long preparation methods
and donor variability. Furthermore, complement control
proteins are at least partially responsible for observed eva-
sion of complement-mediated lysis of HIV virions and are
expressed on primary CD4+ T cells [62-64]. Therefore, we
used PBMC-derived virus isolates in order to produce
virus that closely resembled that produced in vivo, and
developed a novel assay system to study C’-ADE of pri-
mary isolates, using the T cell line SupT1/R5, which natu-
rally expresses CD4, CXCR4 and CR2, and has been
transduced to stably express CCR5 (Figure 1A). Viruses
were incubated with antibody (heat-inactivated patient
serum) and complement (pooled fresh seronegative
human serum; C’), both at a final concentration of 10%,
for 1 hour at 37°C and then added to the SupT1/R5 cells
(Figure 1A). Control experiments were performed in par-
allel in which the patient sera were replaced with pooled
seronegative normal human serum (NHS; antibody-nega-
tive control). In addition to this, the C’ was replaced with
a heat-inactivated equivalent (HIC’; complement-negative
control) in assays of both patient sera and NHS in order
to detect the antibody-only mediated effects on viral repli-
cation (e.g. neutralisation). Infection was detected by intra-
cellular p24 staining and flow cytometry 6 days after
inoculation, and the percentage of infected cells calculated.
Flow cytometry plots, microscopy images and fold
enhancement calculations from a typical enhancement
assay are shown in Figure 1B, C and 1D. In all experi-
ments, results are reported as fold enhancement, mean-
ing the ratio of infection in the presence of autologous
(patient) serum to infection in the presence of NHS, cal-
culated separately for infection in the presence of HIC’
and C’ (Figure 1D). This cancels out the complement-
only enhancement in the assays, which was a virus-spe-
cific effect that ranged from 2 to 10-fold for the viruses
used in this study (Table 1; also evident in Figure 1D),
and allows the data to be presented only in terms of the
additional effect of the HIV-specific antibodies. All
serum samples were assayed at a final concentration of
10% in order to represent the dominant antibody activ-
ity in the sera, rather than diluting sera (as is common
practice in some enhancement assays), which may skew
results by under-representing neutralisation. Only fold
increases that exceeded the stringent cut-off of 5-fold
were scored as enhanced infection, as normal human
serum taken from nine uninfected individuals gave a
mean fold enhancement of 1.85 (range 0.72 - 3.7; stan-
dard deviation from the mean 0.9) compared to the
pooled control serum, NHS.
High-level enhancement of early patient isolates by early
autologous sera
The primary focus of this study was to investigate the
occurrence of C’-ADE in early HIV infection in the
time-frame between seroconversion and the develop-
ment of an autologous neutralising response - a time of
dynamic virus replication and antibody production, dur-
ing which non-neutralising antibodies dominate in the
infected individual [65]. Viruses were isolated from 10
HIV-1 clade B-infected individuals from the Jenner
cohort [1,6] at the earliest time points available, between
6 and 62 days following onset of symptoms characteris-
tic of primary HIV infection (DFOS; Table 1), and
assayed in the presence of sequential autologous serum
samples and exogenous human C’ or HIC’.
Anti-envelope antibodies were detectable (by ELISA)
in all individuals and increased steadily over time (Addi-
tional File 1; Figures S1A and S1B). Total IgG and IgM
were also measured and were within or higher than the
expected range for healthy individuals (data not shown).
The C’-ADE assay design was optimised for measuring
increases in infection, therefore independent neutralisa-
tion assays were carried out on paired plasma samples
from each individual (in the absence of C’) in order to
characterise the development of a neutralising response
in detail (Table 2). The results from the longitudinal C’-
ADE assays and a summary of the neutralisation data
are shown in Figure 2. With the exception of MM27, all
patients showed evidence of high-level C’-ADE activity
(grey squares), with enhancement levels reaching 236-
fold (MM24.26 virus with day 44 serum). The enhancing
effect of the patient sera was complement-dependent, as
the same sera assayed in the presence of HIC’ had only
minimal effect on replication (white squares). The detec-
tion of a neutralising response to the early virus, as
defined by >90% inhibition compared to control cultures
in the independent neutralisation assays (shaded areas),
coincided with the complete disappearance (MM24,
MM25, MM26) or a sharp drop (MM34) of C’-ADE
activity.
We discerned three patterns of C’-ADE of early viruses.
MM24, MM25 and MM26 showed strongest C’-ADE at
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Figure 1 The enhancement assay. (A) Schematic diagram of the assay. (B) Flow cytometry dot plots from a typical enhancement assay. The
gate is set against uninfected control SupT1/R5 cells. The upper panel shows the percentage of SupT1/R5 cells infected by virus pre-incubated
with C’ and NHS control serum, the lower panel with C’ and an example autologous patient serum. (C) Light microscopy images from a typical
enhancement assay. Images were taken of the cells analysed in 1B, prior to intracellular p24 staining and flow cytometry. The upper panel
shows cells infected by virus pre-incubated with C’ and NHS control serum, the lower panel with C’ and autologous patient serum. Arrows on
the upper panel indicate the presence of syncytia, which are large and numerous on the lower panel. (D) Calculation of fold enhancement. All
experiments are performed alongside an HIV-antibody-negative (NHS) control culture, in the presence (C’) and absence (HIC’) of active
complement. Enhancement is observed in the presence of C’, therefore fold enhancement is calculated as the ratio of infected cells in the
presence of C’ and test (patient) serum to infected cells in the presence of C’ and NHS. Figures 1B, C and D are all derived from experiments
using MM32.10 virus and MM32 day 15 autologous serum (see Figure 2). The NHS + C’ control experiments yielded 0.4% infected cells and the
patient serum + C’ cultures 8.8% infected cells, equating to a 22-fold enhancement of infection.
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early time points, with C’-ADE subsiding sharply upon
the appearance of a neutralising response. Neutralisation
occurred between 185 and 253 days following onset of
symptoms (Figure 2 and Table 2). The magnitude of the
C’-ADE differed between the three individuals, with
MM24 showing the highest peak levels (236-fold on day
44), and MM25 the lowest (8-fold on day 31). In con-
trast to this, MM28, MM33, MM34 and MM42 dis-
played C’-ADE for an extended period of time, with
peak C’-ADE occurring between days 200 and 800, and
increases of C’-ADE over time paralleling the increased
production of anti-Env antibodies (Figure 2 and Addi-
tional File 1; Figure S1). In these individuals, there was
also a minor peak of C’-ADE activity before day 50, ana-
logous to the early peak seen for MM24, MM25 and
MM26. For MM34, the emergence of a neutralising
response coincided with a reduction in C’-ADE activity
on day 759 (Figure 2 and Table 2). Neutralising activity
was not detected for MM28, MM33 and MM42 in the
time-frame investigated (Table 2). As with the first
group of individuals (MM24, MM25 and MM26), the
magnitude of the C’-ADE differed between these indivi-
duals, with MM33 showing the highest peak levels (115-
fold on day 719) and MM42 the lowest (19-fold on day
238). C’-ADE was also detected with early virus and sera
from MM32 and MM38, but their longitudinal patterns
of C’-ADE could not be determined due to study opt-
out and commencement of antiretroviral therapy,
respectively. In contrast to all other patients, C’-ADE of
MM27 was variable and below the 5-fold threshold for
genuine C’-ADE (Figure 2).
The observed C’-ADE activity emerges at the same
time as antibodies previously shown to have C’-
Table 2 Neutralisation of early patient viruses by
sequential autologous plasma
Patient MM24
DFOS 44 93 124 208 292 409 464 555 834
IC90 < 10 < 10 < 10 80 320 640 640 640 640
IC50 10 10 10 320 1280 1280 1280 2560 1280
Patient MM25
DFOS 31 38 66 94 185
IC90 < 10 < 10 < 10 < 10 10
IC50 < 10 < 10 < 10 < 10 40
Patient MM26
DFOS 55 76 83 111 139 169 253 337 474
IC90 < 10 < 10 < 10 < 10 < 10 < 10 10 40 80
IC50 < 10 < 10 < 10 < 10 < 10 10 40 160 320
Patient MM27
DFOS 46 53 109 299 585 755
IC90 < 10 < 10 < 10 < 10 < 10 < 10
IC50 < 10 < 10 < 10 < 10 < 10 < 10
Patient MM28
DFOS 20 34 62 93 198 405 503 782 950
IC90 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
IC50 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 20
Patient MM32
DFOS 10 14 21
IC90 < 10 < 10 < 10
IC50 < 10 < 10 < 10
Patient MM33
DFOS 26 33 69 96 201 523 621 719
IC90 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
IC50 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
Patient MM34
DFOS 32 45 74 192 443 607 759
IC90 < 10 < 10 < 10 < 10 < 10 < 10 10
IC50 < 10 < 10 < 10 < 10 < 10 < 10 10
Patient MM38
DFOS 29 36 51 58 93
IC90 < 10 < 10 < 10 < 10 < 10
IC50 < 10 < 10 < 10 < 10 < 10
Patient MM42
DFOS 22 29 36 43 57 92 183 238 324
IC90 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
IC50 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10 < 10
Early patient viruses (detailed in Table 1) and sequential autologous plasma
samples were analysed by standard TZMbl neutralisation assay. Plasma time
points are represented by DFOS (days following onset of symptoms) as for
serum samples used throughout this study. IC50 and IC90 values represent
the highest plasma dilution at which reductions in infection of 50 and 90%,
respectively, are achieved relative to control cultures.
Table 1 Patient primary virus isolates




MM24 MM24.26 26 2.2
MM24.464 464 2
MM25 MM25.18 18 2.4
MM26 MM26.62 62 2.1
MM26.384 384 3.6
MM27 MM27.28 28 2
MM27.585 585 3.8
MM28 MM28.6 6 2.1
MM32 MM32.10 10 3.1
MM33 MM33.12 12 3.4
MM34 MM34.32 32 9.7
MM34.443 443 2.1
MM38 MM38.29 29 3.8
MM42 MM42.29 29 1.9
MM42.238 238 2
Virus isolates are named according to patient ID (e.g. MM24) followed by a
decimal point then the day of virus isolation. Days represent the time following
onset of symptoms indicative of acute HIV infection. Viruses were isolated from
patient PBMCs by co-culture, and expanded by minimal passage in fresh
PBMCs. Fold increases in infection seen in the presence of complement alone
(C’; i.e. in the absence of HIV-specific antibodies) compared to in the presence
of heat-inactivated complement (HIC’) are shown for each virus.
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mediated inactivation (C’-MI) activity [6]. However, as
lysis was not considered the principal mechanism of C’-
MI it is possible that the same antibodies can mediate
both C’-ADE and C’-MI effects, but that the outcome is
determined by the target cell. In order to place the
observed C’-ADE activity in the context of the various
antibody functions observed at early time points follow-
ing infection, Additional File 2; Figure S2 shows the
longitudinal C’-ADE, C’-MI and neutralisation profiles
for one of the patients (MM26). Both C’-ADE and C’-
MI are seen prior to the development of neutralising
antibodies, hence non-neutralising antibodies produced
early in infection can mediate both C’MI and C’ADE,
although it cannot be excluded that the distinct activ-
ities of the whole sera tested in different assay condi-
tions may be attributable to different types of antibodies
within the sera.
To relate our results back to previously reported C’-
ADE studies, we tested a known enhancing monoclonal
antibody (mAb), 246-D, in our system. 246-D enhanced
infection of the TCLA strain IIIB up to 3.7-fold,
comparable to previous reports with enhancing mAbs
[34,39], and showed only limited enhancement of the
patient isolate MM38.29 (Additional File 3; Figure S3).
As a control, a known neutralising mAb, IgGb12, was
tested alongside 246-D and expected neutralisation
results were obtained.
For further comparisons with previous C’-ADE stu-
dies, serum samples from MM24, MM25, MM26 and
MM27 were tested with IIIB. Fold enhancement levels
of no greater than 6-fold were observed (data not
shown), also consistent with previous reports of C’-ADE
[25,28,41,66], and demonstrating that the high level of
enhancement seen with the patient isolates is not a uni-
versal feature of our system.
C’-ADE increases the number of cells infected, virus
output and cell death
The enhanced infection evident in Figure 1 and 2 was also
detectable when infection was measured by alternative
methods, including reverse transcriptase (RT) output as a
measure of virus production and percentage (%) cell loss
Figure 2 High-level C’-ADE of early viruses by autologous sequential sera. Serum sets from 10 patients were tested against autologous
virus for C’-ADE activity. Sera and virus time points are shown as days following onset of symptoms characteristic of primary HIV infection
(DFOS). Arrows indicate the time point from which virus was isolated. White squares represent assays conducted in the presence of HIC’; grey
squares, C’. Error bars represent standard deviations from 3 experiments. To show clearly events pre-day 100 (during which the antibody
response is developing rapidly and sampling is more frequent), breaks have been inserted into the X-axes. Post day-100 intervals = 100 days.
Shading indicates the first appearance and continued detection of an autologous neutralising antibody response (as determined by >90%
neutralisation in an independent neutralisation assay). The horizontal dashed blue line indicates the cut-off point for positive C’-ADE. Note that
the scales of the Y-axes differ between subjects. The datum point equating to the enhancement depicted in Figure 1 B, C and D (MM32.10
virus with day 15 autologous serum) is circled in red.
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(Table 3 and Additional File 4; Figure S4). C’-ADE trans-
formed a low-level infection (0.2% cells infected; 0% cell
loss compared with uninfected control cultures) to a
highly destructive one (46% cells infected; 80% cell loss
compared with uninfected control cultures). The increased
detection of virus (RT) in the cell supernatant over time
(Additional File 4; Figure S4A), along with clear evidence
of cytopathic effect (Figure 1C), indicates increased pro-
ductive infection and ongoing virus replication in the
enhanced cultures.
The observed C’-ADE was mediated by CR2, with
increased attachment to the target cell the primary
mechanism
Limited investigation has been carried out on the
mechanisms of C’-ADE occurring through CR2, and the
ability of CR2 to mediate these effects on various cell
types. Potential ways in which C’-ADE could occur
through CR2 include: increased attachment of the virus
to the target cell, resulting in increased efficiency of
entry; signalling through the receptor resulting in endo-
cytosis of the virus and subsequent infection via an
alternative pathway; signalling through the receptor to
suppress intracellular antiviral activity; or signalling
through the receptor to increase viral replication.
In order to formally demonstrate that the C’-ADE
observed was mediated by CR2, and to exclude the
involvement of other molecules on the SupT1/R5 cells,
we performed studies using the mAb 1048, known to
block the binding of the complement factor C3 d to
CR2 [67], and the anti-CR2 mAb 1F8 as a control,
which binds to CR2 but does not prevent its C3 d
binding activity [68]. Both antibodies recognised CR2
on the SupT1/R5 cells (Figure 3A). Cells were incu-
bated with increasing concentrations of 1048 or 1F8
for 30 minutes at room temperature, washed, then
used as target cells in enhancement assays. Initial anti-
CR2 mAb titration experiments using MM34.443 virus
and day 443 autologous serum demonstrated that 1048
completely abolished C’-ADE activity at concentrations
greater than 1 μg/ml, whereas 1F8 had no effect on
infection or C’-ADE up to 50 μg/ml (Figure 3B). A
further three subjects (MM24.464 virus with MM24
day 292 serum; MM27.585 virus with MM27 day 299
serum; and MM32.10 virus with MM32 day 21 serum)
were then tested at C’-ADE-inhibitory concentrations
of the blocking mAb (10 μg/ml). As before, for all
three subjects the 1F8 control mAb had no effect on
C’-ADE, while the blocking mAb 1048 abrogated C’-
ADE activity (Figure 3B).
To investigate the role of receptor signalling, and thus
the mechanism of C’-ADE, full-length and truncated CR2
(lacking the cytoplasmic tail, ΔCT) constructs were cloned
and expressed in the HIV-permissive cell line NP2/CD4/
R5 (Figure 3C). One late patient virus, MM24.464, and
two early patient viruses, MM32.10 and MM33.12, were
opsonised with known enhancing autologous sera, MM24
day 292, MM32 day 15 and MM33 day 719 respectively,
plus HIC’ or C’, before addition to NP2/CD4/R5 control,
CR2+ or ΔCT+ cells. High-level C’-ADE of all three
viruses occurred on the CR2+ and ΔCT+ cells; C’-ADE
did not occur on the control cells (Figure 3D). Infection
with MM24.464 was enhanced 48-fold on the CR2+ cells
and 40-fold on the ΔCT+ cells, compared with 189-fold in
the equivalent SupT1/R5 assay. Infection with MM32.10
virus was enhanced 9-fold on the CR2+ cells and 7-fold
on the ΔCT+ cells, compared with 24-fold in the equiva-
lent SupT1/R5 assay (Figure 2). Infection with MM33.12
was enhanced 42-fold on the CR2+ cells (light microscopy
images of which are shown in Figure 3E) and 20-fold on
the ΔCT+ cells; equivalent enhancement assays carried
out on SupT1/R5 cells resulted in a 115-fold enhancement
(Figure 2). As C’-ADE can occur in the absence of the
CR2 cytoplasmic tail, signalling processes through CR2 are
not an essential part of the C’-ADE mechanism. Enhanced
infection, through increased attachment of the virus to the
target cell, is, therefore, likely to be the principal mechan-
ism of C’-ADE.
C’-ADE activity is present in both IgG and IgM plasma
fractions, but IgG showed the most potent C’-ADE activity
To confirm that the C’-ADE mediated by patient serum
was attributable to the immunoglobulin fraction, and to
investigate the contributions of the IgG and IgM frac-
tions, IgG and IgM were purified from early, late and
seronegative control plasma (NHP) in parallel. Both IgG
and IgM purified from early (day 26) plasma from
MM24 were capable of enhancing infection of the
Table 3 Enhancement is characterised by increased cell infection, increased virus production and increased cell death
Parameter Assay NHS + C’ Day 44 serum + C’ Fold enhancement
% infected cells Intracellular p24 stain 0.20 46.1 236
% viable cells MTT 101 20 N/A
RT production (pg/ml) RT ELISA 222 20495 92
To further characterise the enhancement and elucidate whether the flow cytometry results obtained were representative of productive infection, reverse
transcriptase (RT) output (to quantitate virus production) and percentage (%) cell death (normalised to uninfected control cultures) were measured by RT ELISA
and MTT assay, respectively. Results shown are from enhanced and control infection of MM24.26 virus. Experiments were carried out in the presence of C’, with
fold enhancement calculated by dividing infection levels in the presence of patient serum (MM24 day 44) by infection in the presence of control serum (NHS).
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Figure 3 C’-ADE is mediated by CR2 and can also be mediated by a mutant CR2 lacking a cytoplasmic tail. (A) Binding of two anti-CR2
mAbs, 1048 and 1F8, to SupT1/R5 cells was tested by flow cytometry. Both antibodies recognise a C3d-binding region-containing portion of
CR2, but only 1048 blocks ligand binding. Both are shown to bind SupT1/R5 cells, at 10 μg/ml. (B) Left panel: the involvement of CR2 in C’-ADE
was initially investigated by pre-incubating SupT1/R5 cells with increasing concentrations of C3dg ligand-blocking mAb 1048, and non-blocking
mAb 1F8 as a control, before performing enhancement assays as usual, with MM34.443 virus and day 443 autologous serum. Right panel: a
further three subjects (MM24.464 virus with day 292 serum; MM27.585 virus with day 299 serum; MM32.10 virus with day 21 serum) were tested
in the presence of 10 μg/ml 1F8 or 1048 mAb. All experiments were performed in the presence of C’, and fold enhancement was calculated
relative to infection in the presence of NHS + C’ and in the absence of anti-CR2 mAbs. (C) NP2/CD4/R5 cells stably expressing CR2 and CR2ΔCT
were established by retroviral vector transduction. Expression levels were determined by flow cytometry using an anti-CR2 mAb. (D)
Enhancement experiments were carried out on NP2/CD4/R5 (control; ctrl), NP2/CD4/R5/CR2 (CR2) and NP2/CD4/R5/CR2Δcytoplasmic tail (ΔCT)
cells using MM24.464 virus opsonised with day 292 autologous serum, MM32.10 virus opsonised with day 15 autologous serum, and MM33.12
virus opsonised with day 719 autologous serum, and HIC’ (white bars) or C’ (black bars). Fold enhancement was calculated relative to infection in
the presence of NHS + HIC’ or NHS + C’, as appropriate, on each cell line. Error bars represent standard deviations from 3 experiments. (E)
Images of the enhanced infection of MM33.12 virus by day 719 autologous serum on NP2/CD4/R5/CR2 cells. The left-hand image shows
infection in the presence of NHS + C’, and the right-hand image infection in the presence of day 719 serum + C’.
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autologous early virus (MM24.26), with the IgG enhan-
cing to a greater magnitude (Figure 4). Late (day 292)
IgM continued to enhance MM24.26, whereas the late
IgG, in keeping with the late serum, neutralised
MM24.26.
Later virus isolates from the same individuals are
enhanced to a greater degree than early isolates
In the face of an emerging neutralising antibody
response, virus evolution in infected individuals is rapid
and ongoing [4,5,9,10]. We therefore investigated
whether virus isolates from chronic infection (taken
from between 238 and 585 days following onset of
symptoms; Table 1) from 5 individuals maintained the
capacity for enhanced infection. Two later viruses were
tested from individuals that showed strong early C’-ADE
and then neutralisation of early virus (MM24 and
MM26; Figure 2), one from the individual that did not
show C’-ADE of early virus (MM27; Figure 2), and two
from individuals that showed C’-ADE of early virus for
an extended period of time with peak levels post day
200 (MM34 and MM42; Figure 2). C’-ADE profiles for
both early and late viruses from these five individuals
are shown in Figure 5.
With the exception of MM24.464 virus, for all of the
later viruses tested the peak C’-ADE activity occurred in
the serum sample obtained on or immediately before
the day the virus was isolated. For MM24.464, the peak
C’-ADE activity occurred 340 days earlier with day 124
serum (356-fold enhancement). For both MM24 and
MM26, sera that neutralised the early viruses enhanced
the later viruses. C’-ADE activity of MM24.464 virus
was 326-fold with day 208 serum, whereas day 208
serum neutralised MM24.26 virus. Similarly, the peak
C’-ADE activity of MM26.384 virus was 32-fold with
day 384 serum, whereas day 384 serum potently neutra-
lised MM26.62 virus. Although no C’-ADE was detected
when the early MM27 virus (MM27.28) was assayed, the
later MM27 virus (MM27.585) was enhanced by autolo-
gous sera, peaking at 286-fold with day 299 serum.
Thus, although MM27 serum does not enhance
MM27.28 virus, it does not lack C’-ADE activity. For
MM34 and MM42, the same profile of C’-ADE seen for
the early viruses was maintained for the later viruses,
but at an overall higher magnitude. C’-ADE peaked on
day 443 for MM34, with MM34.32 enhanced 27-fold
and MM34.443 enhanced 92-fold. For MM42 C’-ADE
peaked on day 238, with MM42.28 enhanced 19-fold
and MM42.238 enhanced 30-fold.
With the exception of patient MM24, whose early virus
MM24.26 was already enhanced to a high level by contem-
poraneous serum (143-fold), later virus isolates from
infected individuals were enhanced by contemporaneous
sera to a significantly greater degree than early isolates
(Table 4). Even later viruses that did not appear to escape
a neutralising response (as NAbs were not detected by the
time of isolation) were enhanced to a greater extent.
Importantly, for MM34 and MM42 the patterns of C’-
ADE over time were the same, but for the later viruses the
magnitude of fold enhancement was greater. These find-
ings indicate that the reason for the increased enhance-
ment is not necessarily that the later viruses are less
susceptible to neutralisation (i.e. that levels of enhance-
ment are inversely related to levels of neutralising antibo-
dies in sera), but that other properties of the later viruses
make them more susceptible to enhancement.
Further characterisation of enhancing and neutralising
IgG
As shown previously in Figure 4 IgG purified from
MM24 early and late plasma enhanced and neutralised
MM24.26 virus, respectively. To further characterise the
neutralising and enhancing activity in early and late
plasma against both early and late viruses, IgG was puri-
fied from MM24 day 44 and 464 plasma (different time
points from those in Figure 4 were used due to limited
availability of material) and used in titration experi-
ments. IgG concentrations in the plasma samples used
for the purification, and the IgG eluted from the purifi-
cation columns, were determined by IgG ELISA and the
dilutions of purified IgG used in the assays adjusted
relative to the original plasma IgG concentration. As
expected, at the highest concentration tested, early and
late MM24 IgG enhanced and neutralised MM24.26
virus, respectively, reflecting the properties of the
patient sera (Figure 2 MM24 and Figure 6 MM24.26).
Figure 4 C’-ADE activity of purified IgG and IgM. IgG and IgM
were purified from early (day 26) and late (day 292) plasma from
MM24 and tested against MM24.26 virus in the presence of C’ on
SupT1/R5 cells. Fold enhancement was calculated relative to
infection in the presence of IgG or IgM purified from NHP, or whole
NHS, as appropriate, and C’. Error bars represent standard deviations
from 3 experiments.
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Upon dilution, the early, enhancing IgG became less
enhancing, whereas the late, neutralising IgG gained
enhancing activity (Figure 6 MM24.26). Both early and
late IgG enhanced the later MM24.464 virus, and this
enhancing activity declined with dilution (Figure 6
MM24.464). These data, along with the temporal disap-
pearance of C’-ADE upon the detection of a neutralising
response (Figure 2), indicate that the presence of a
robust neutralising activity can mask underlying enhan-
cing activity.
Heterologous cross-reactivity of C’-ADE but not
neutralisation
To investigate the breadth of the C’-ADE response, virus-
sera sets from three patients (MM25, MM27 and MM33;
Figure 2) were assessed for heterologous C’-ADE activity
(Figure 7). The heterologous C’-ADE profiles show that
the pattern of C’-ADE over time was a property of the
serum whilst the magnitude of the C’-ADE was a prop-
erty of the virus. The MM27.28 virus was interesting as
this virus was not enhanced by autologous sera, yet was
enhanced by MM25 and MM33 sera, albeit at the low
levels of 9- and 10- fold respectively. Conversely, MM27
sera could enhance other viruses, with peaks of 25-fold
for MM33.12 virus and 10-fold for MM25.18. This
implies that characteristics of both MM27 virus and sera
together, rather than either alone, limited C’-ADE in the
autologous assays. While all sera tested that showed C’-
ADE of autologous virus also showed C’-ADE of hetero-
logous virus, the MM25 day 185 serum that neutralised
autologous virus did not show cross-neutralising activity
of heterologous viruses.
Figure 5 C’-ADE of early and late viruses from 5 patients by autologous sequential sera. Viruses isolated at early and late time points
following onset of symptoms were assayed on SupT1/R5 cells in the presence of C’ and sequential autologous sera. Arrows indicate early and
late virus isolation times. Grey squares represent assays performed with early virus (as in Figure 2); yellow circles with late virus. The horizontal
dashed blue line indicates the cut-off point for positive C’-ADE. Note that the scales of the Y-axes differ between subjects. Error bars represent
standard deviations from 3 experiments.
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Discussion
Here we have shown that infectivity of primary isolates
from individuals with early HIV infection can be
enhanced over 350-fold when opsonised with autolo-
gous antibodies and complement, compared with infec-
tion in the presence of complement alone. The range
of increases in infection are comparable to those
reported for dengue virus, a disease in which ADE
contributes to pathogenesis during secondary infection
by a different serotype and in infants carrying sub-neu-
tralising levels of maternal antibodies [44,46,47,69,70].
Previous studies using X4-tropic TCLA strains of HIV,
or primary isolates opsonised with complement alone,
typically showed up to 10-fold increases in infection
[25,28,36,41,42,66], as we have also confirmed when
performing similar experiments. A well-characterised
enhancing mAb, 246-D, enhanced infection of the
TCLA HIV strain IIIB by up to 3.7-fold in our assay
system, whereas the same mAb showed a very modest
enhancement of the patient primary isolate MM38.29.
The same patient primary isolate was enhanced up to
46-fold by autologous serum. We attribute the high
level of C’-ADE shown in this study to the use of pri-
mary clinical isolates of HIV and their autologous anti-
bodies on T cells able to support infection by R5-
tropic viruses. The high levels reported here suggest
that C’-ADE may be an important infection-enhancing
mechanism in vivo. Furthermore, access to a cohort of
recently infected individuals allowed us to perform
longitudinal studies of C’-ADE and provided us with a
unique perspective of the development of this response
over time. Later virus isolates were enhanced more
than early isolates from the same individuals, indicat-
ing that the C’-ADE observed in our model system
reflects a replicative advantage for the enhanced
viruses in vivo.
Most HIV antibody assays in vitro are carried out in
the absence of complement, yet, in vivo, cell-free HIV is
likely to be opsonised with antibodies and complement
at all stages of disease post-seroconversion [71]. Given
that complement can modulate antibody activity, it is
logical to consider the effects of complement alongside
any study of antibodies. Furthermore, HIV replicates
predominantly in lymphoid tissues, which are rich in
immune cells expressing CRs, including macrophages,
DCs, and some T cells and B cells [11,71]. We have
shown that the presence of a CR on an HIV target cell
can drastically alter the outcome of virus opsonisation
with antibodies and complement. We have shown that
sera with apparently no activity when assayed on CR-
negative cells (Table 2 and Figure 3), or with virus-inhi-
bitory activity when assayed on CR-negative cells in the
presence of complement (Additional File 2; Figure S2),
can enhance infection by several orders of magnitude on
Table 4 Comparison of C’-ADE levels in contemporaneous
autologous virus-serum pairs for early and late viruses
Patient Day of virus isolation Contemporaneous
serum enhancement
p value
MM24 26 143 N/A*
464 76
MM26 62 18 0.02
384 32
MM27 28 4 0.008
585 50
MM34 32 7 < 0.001
443 92
MM42 29 6 < 0.001
238 30
* decreased, rather than increased, C’-ADE.
Fold enhancement (in the presence of C’) is shown for contemporaneous
serum with early and late viruses. P values are derived from a two-tailed
Student’s T test assuming equal variance, based on the null hypothesis that
the two means are equal. All but one of the later virus isolates (MM24.464)
are enhanced to a level significantly greater than that of the early viruses
when tested with paired contemporaneous serum.
Figure 6 Titration of antibodies purified from enhancing and
neutralising serum. IgG was purified by Protein G affinity
chromatography from patient plasma taken on the same day as
sera that enhanced and neutralised early patient virus, days 44 and
464 respectively. 10-fold serial dilutions of d44 and d464 IgG were
tested against early autologous virus (MM24.26) and late autologous
virus (MM24.464). The X-axes indicate IgG dilutions assayed relative
to the IgG concentration in the original plasma source. Fold
enhancement was calculated relative to infection in the presence of
IgG purified from NHP. Identical assays performed with sera in the
place of purified IgG are shown in the bottom panel for
comparison. The horizontal dashed blue line indicates the cut-off
point for positive C’-ADE. Error bars represent standard deviations
from 3 experiments.
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CR-positive cells in the presence of complement (both
on T cells naturally expressing CR2, and on unrelated
cells engineered to express CR2; Figure 2, Figure 3,
Additional File 2; Figure S2).
The C’-ADE observed in our model system could
represent a variety of processes mediated through CRs
in vivo. Through analogy with previous reports carried
out with virus opsonised with complement alone, these
could include direct infection-enhancement of CR+ tar-
get cells, enhanced B cell-to-T cell or DC-to-T cell
trans-infection, or enhanced FDC trapping of comple-
ment- and antibody-opsonised virions [35-38,72-77], all
of which could influence HIV pathogenesis. For exam-
ple, CR2 has been implicated in HIV trapping, archiving
and trans-infection of T cells mediated by B cells and
FDCs [73-78]. The high levels of enhancement seen
Figure 7 C’-ADE by heterologous sera. Early viruses and sequential serum sets from 3 patients were tested against each other to investigate
heterologous C’-ADE. The patient from whom the virus was derived is indicated on the far left, and serum at the top. White squares represent
assays conducted in the presence of HIC’; grey squares, C’. The horizontal dashed blue line indicates the cut-off point for positive C’-ADE. Note
that the scales of the Y-axes differ between subjects. Error bars represent standard deviations from 3 experiments.
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here through CR2 may reflect an important role for
non-neutralising, enhancing antibodies in these pro-
cesses in vivo, and may be particularly relevant to early
B cell-mediated viral dissemination and subsequent FDC
trapping. In addition to B cells and FDCs, CR2 expres-
sion has been reported on T cell subsets [79-84], thymo-
cytes [82,85,86] and astrocytes [87], which may support
directly enhanced infection by HIV.
The principal complement component ligands of CR2
are the C3 fragments C3dg and C3 d, and to a lesser
extent iC3b [71,88]. The enhancement reported here
through CR2 might also occur through other receptors
for C3 complement fragments, namely CR1, CR3 and
CR4 [71]. Complement alone has been shown to sub-
stantially increase infection of primary monocytes/
macrophages and DCs expressing CRs [35-38], and
enhancing antibodies may augment this process by
increasing the deposition of complement on the virion.
However, effects mediated through CRs may be counter-
acted by reported virus-inhibitory effects mediated
through FcRs on macrophages and DCs [37,89], and the
net outcome may be influenced by the receptor balance
on the target cell and the nature of the antibodies
[36,37]. Future evaluation of CR and FcR expression on
primary cell targets for HIV, and investigation of the
role of these receptors in enhancing and inhibiting HIV
infection, is warranted.
In agreement with results obtained by Montefiori and
colleagues in a macaque model of acute SIV infection
[90], the presence or emergence of neutralising activity
masks pre-existing enhancing activity. This is shown
here by the temporal disappearance of enhancing activ-
ity upon the detection of a potent neutralising response
(Figure 2 and Table 2), and by detection of enhance-
ment upon dilution of neutralising IgG (Figure 6).
Mechanistically, this could be because abundant non-
neutralising antibodies enhance infection through
increasing attachment to the target cell, while the neu-
tralising antibodies are ultimately able to block entry of
the virus if present in sufficient quantities, whether it is
through enhanced or direct infection.
Our studies of heterologous virus-serum pairs show
that enhancing, but not neutralising, activity can be
transferred to heterologous viruses, perhaps because the
enhancing antibodies are directed to more conserved,
non-neutralising, immunodominant epitopes. Yet, this
does not equate with any antibody having the potential
to enhance - it is likely that antibodies must be of a rea-
sonable affinity and concentration for enhancement to
occur. Early studies of C’-ADE of HIV demonstrated an
association between gp41 antibodies and C’-ADE activity
[91,92]. A key “enhancing domain” was identified within
the PID of gp41, in a region primarily accessible on dis-
assembled or post-fusion envelope spikes [93]. The
association between C’-ADE and gp41 antibodies may
be of particular relevance to the acute stage of HIV
infection, when the first antibodies produced in
response to infection are directed against gp41 and are
non-neutralising [2].
Laboratory preparations of HIV, and cell-free HIV
present in plasma of infected individuals, are often
attributed with low infectivity relative to the number of
physical virus particles present, with discrepancies
between infectious units and physical virus particles esti-
mated to be as high as 1 to 60,000 [94-96]. The tradi-
tional explanation for this is a high level of “defective”
viral particles, produced as a consequence of the error-
prone nature of reverse transcriptase and the labile nat-
ure of the viral envelope proteins. An alternative expla-
nation is that, due to a relatively low efficiency of initial
cellular receptor engagement [97], coupled with the low
number of trimeric envelope spikes on the viral surface
[98], the infectivity of HIV is underestimated because
the vast majority of virus particles in a preparation lack
the opportunity to infect the target cells [99]. This is
supported by other demonstrations of dramatic
enhancement of HIV infectivity in vitro, through coating
of HIV with semen amyloid fibrils [100], incorporation
of host attachment proteins into the viral membrane
[101], and direct interactions between gp120 and C-type
lectin receptors on target or bystander cells [102,103];
all are mechanisms that stabilise the virus on the target
cell and improve the efficiency of receptor interaction. It
is unclear to what extent these mechanisms would func-
tion in vivo when the virus is coated with antibodies
and complement. The possibility of C’-ADE also draw-
ing on the so-called “non-infectious” pool of virions, as
opposed to increasing the replication of readily infec-
tious virions, is supported by our studies of the mechan-
ism of C’-ADE, which show that a version of CR2
lacking a cytoplasmic tail (and consequently lacking sig-
nalling ability) supports high-level C’-ADE. Under these
conditions, increased attachment to the target cell is the
most likely mechanism of C’-ADE.
In conclusion, our study highlights the possibility that
antibodies with seemingly no activity in standard cell-
based neutralisation assays may have other activities
when assayed under conditions that accommodate effec-




Blood samples were obtained from a cohort of indivi-
duals recently infected with HIV-1 subtype B, as pre-
viously described [1,6]. All individuals were men who
have sex with men (MSM) presenting with primary HIV
illness (PHI) following sexual exposure to HIV. Blood
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samples were obtained weekly for the first month,
monthly for 3 months and subsequently every 3 months.
Plasma, serum, and whole blood were divided into ali-
quots and stored at -80°C. PBMCs were isolated by
Ficoll gradient centrifugation and stored in liquid nitro-
gen. The study protocol was approved by the Camden
and Islington NHS Trust Ethics Committee and written
informed consent obtained from all subjects. Approval
for the use of human serum, plasma and peripheral
blood leukocytes from healthy volunteers was granted to
Professor R. Weiss by the University College London
Committee on Ethics (project ID 0335/001).
Patient sera, control sera, complement and monoclonal
antibodies
The patient serum samples used as an antibody source
were aliquoted and heat inactivated (56°C for 1 hour)
before use, and complement (referred to as C’ in the
assays) was added back into the system as an exogenous
source in the form of pooled serum from four HIV-ser-
onegative individuals. Due to the labile nature of com-
plement proteins, pooled complement was aliquoted and
immediately stored at -80°C for a maximum of 3
months, and thawed only once before use. In all assays
containing complement, a heat-inactivated equivalent
(HIC’) was used in parallel as a control. The HIV anti-
body-negative control serum (normal human serum;
NHS), was pooled commercial human serum (PAA
Laboratories, Somerset, UK), also heat inactivated for 1
hour at 56°C, aliquoted and stored at -80°C until use.
Previously characterised positive control sera (QC sera
[104]), used in ELISAs, were from three individuals with
chronic HIV infection, and were also heat inactivated
and aliquoted before use. The anti-gp120 mAb IgGb12
[105] was kindly provided by D. Burton, Scripps Insti-
tute, La Jolla, US. mAb 4E10 [106] was obtained from
Polymun Scientific GmbH, Vienna, Austria. 246-D [91]
was obtained through the NIH AIDS Research and
Reference Reagent Program, NIH, US, from S. Zolla-
Pazner.
Viruses
All patient primary isolates were propagated in PBMCs
with minimal passage. PBMCs were isolated by Ficoll
gradient centrifugation from fresh blood drawn from
healthy HIV-negative volunteers. Purified PBMCs were
stimulated with 0.5 μg/ml PHA and cultured for 2 days,
then treated with 5 U/ml human IL-2 for a further 3
days. 1-2 × 107 cells from two different donors were
used for co-culture with 5 × 106 unstimulated patient
PBMCs (collected from whole blood of infected indivi-
duals by Ficoll gradient centrifugation at the time points
specified) or inoculation with 1 ml virus supernatant, for
2 hours at 37°C. Fresh growth medium was added and
the cells incubated at 37°C for 7 days. On days 8, 15
and 22 post-inoculation, cells were split, cell superna-
tants were cleared by centrifugation, and cultures were
replenished with fresh PBMCs, prepared as above. Viral
production was monitored using a commercial p24
ELISA (Biomerieux, France), and virus titres from peak
days of p24 production were determined on NP2/CD4/
CCR5 and NP2/CD4/CXCR4 cells, as detailed below.
The TCLA virus IIIB was propagated in the T cell line
H9.
Cell lines
The human glioma cells lines NP2/CD4/CCR5 and
NP2/CD4/CXCR4, described elsewhere [107], were
kindly provided by H. Hoshino. SupT1 cells transduced
to stably express CCR5 were kindly provided by J.
Hoxie. TZMbl, H9, C8166 and Molt-4 cells were
obtained from NIBSC, UK. MT-2 and MT-4 cells were
obtained from D. Richman through the AIDS Research
and Reference Reagent Program, Division of AIDS,
NIAID, NIH.
Detection of anti-gp120 antibodies
Antibodies to gp120 in patient sera were detected by
ELISA as previously described [1]. Briefly, 96-well Maxi-
sorb plates (Nalgene, Nunc International) were coated
with 10 μg/ml sheep polyclonal anti-gp120 antibody
(D7324; Aalto Bio Reagents, Dublin, Ireland) overnight,
blocked with 1% milk powder, and saturated with HIV-
1IIIB gp120 (EVA657, NIBSC, UK). For each serum sam-
ple to be tested, a blank well excluding the gp120 was
included. Sera were serially tenfold diluted in TMT/GS
(Tris-buffered saline containing 0.05% Tween 20, 4%
milk powder and 10% goat serum), added to the plate
and incubated for 1 hour at room temperature. Bound
antibodies were detected with alkaline phosphatase
(AP)-conjugated goat anti-human Ig (Harlan SeraLab,
Crawley Down, UK), followed by AP substrate solution
(LumiPhos Plus, Aureon Biosystems, Vienna, Austria).
Relative light units were determined at 405 nm. QC sera
(pooled sera from 3 chronically infected individuals,
[104]), and the anti-gp120 mAb IgGb12, were used as
positive controls to enable the standardisation of read-
ings from different plates for direct comparison of anti-
body levels between patients.
Detection of anti-gp41 antibodiess
96-well Maxisorb plates (Nalgene, Nunc International)
were coated with 0.05 μg/well recombinant gp41
(derived from IIIB; ARP680 NIBSC) in 0.1 M sodium
bicarbonate coating buffer, washed in TBS-T (0.05%
Tween in 1× TBS), blocked with TMT/GS (10% goat
serum and 2% milk powder in TBS-T), washed in TBS-
T and incubated with patient or control serum diluted 1
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in 1,000, 5,000 and 25,000 in TMT/GS, for 1 hour at
room temperature. For each serum sample to be tested,
a blank well excluding the gp41 was included for back-
ground subtraction. As for the gp120 ELISA, pooled QC
serum [104]) and an anti-gp41 mAb, 4E10, were used as
positive controls and to standardise readings from dif-
ferent plates.
Titration of virus stocks
NP2/CD4/R5 and NP2/CD4/X4 cells were seeded in 48-
well plates one day prior to infection, at a density of 2 ×
104 cells/well. Tenfold serial dilutions of viral stocks
were added to the cells in triplicate and incubated for 2
hours at 37°C. Cells were then washed, overlaid with
500 μl culture medium and incubated for 48 hours at
37°C. Culture medium was then removed and the cells
fixed for 10 min at room temperature in methanol/acet-
one (1:1 v/v), pre-cooled at -40°C, followed by washing
in PBS. In situ p24 staining was used to detect infection,
as described previously [1]. Viral titres, expressed as
focus forming units (FFU)/ml, were determined by
counting foci by light microscopy.
Neutralisation and C’-MI assays
Neutralisation assays were carried out using two differ-
ent methods: our NP2/CD4/R5-based assay, as pre-
viously described [1,6], and a widely adopted TZMbl-
based assay [108]. For the TZMbl assays, a viral input of
200 TCID50 and incubation time of 48 hours were used.
% neutralisation was calculated relative to the virus con-
trol, with the IC90 values reported being the last dilu-
tion of each plasma sample to give greater than 90%
reduction of infection.
For the NP2/CD4/R5 assay, 200 focus-forming units
(FFU) of virus were incubated with patient plasma or
normal human plasma (NHP) as a control, in a final
volume of 100 μl for 1 hour at 37°C. Patient plasma and
NHP were each used at a standard concentration of 10%
at the time of incubation. Medium was removed from
cells and replaced with the virus-plasma mixtures, and
incubated for 2 hours at 37°C. Cells were then washed
once in culture medium, replenished with fresh culture
medium and incubated for 48 hours at 37°C. Cells were
then fixed and stained in situ for p24 expression [1] and
foci were counted by light microscopy. % neutralisation
was calculated relative to the NHP control.
Complement-mediated inactivation (C’-MI) assays
were performed in a similar way to the NP2/CD4/R5
neutralisation assays [6], with the exception that patient
serum (rather than patient plasma) was used as an anti-
body source, and NHS used as a control. Complement
(C’), or heat-inactivated complement as a control (HIC’),
was also added at a final concentration of 10% (v/v) [6].
% inactivation was calculated relative to the NHS control.
SupT1/R5 enhancement assay
Virus (input equivalent to an endpoint of 0.1% infected
cells in the presence of NHS and HIC’) was incubated
with C’ (or HIC’ as a complement-negative control) and
patient serum (or NHS as an antibody-negative control)
in a total volume of 100 μl for 1 hour at 37°C. When
patient sera were serially diluted, or when mAbs were
used as an antibody source, dilutions were performed in
NHS to maintain a consistent level of serum in the
assay. C’/HIC’ and patient serum/NHS, as appropriate,
were each used at a final concentration of 10% at the
time of incubation. Virus-serum mixtures were next
transferred to SupT1/R5 cells, seeded at 105 cells per
well in U-bottomed 96-well tissue culture plates, giving
a final volume of 200 μl per well. 100 μl of cell superna-
tant was removed on days 1 and 3 after inoculation for
RT ELISA analysis (Cavidi, Sweden), and replaced with
100 μl fresh culture medium. On day 6 after inoculation,
all cell supernatant was removed and stored for RT
ELISA analysis, and the cells were stained for intracellu-
lar p24 expression and subsequent FACS analysis.
Intracellular p24 stain, determination of percent infected
cells and calculation of fold enhancement
Cells were fixed in 3.8% formaldehyde solution, washed
once in staining buffer (PBS with 1% FCS and 0.1%
sodium azide) and once in permeabilisation buffer
(PERM buffer; staining buffer with 0.5% (w/v) saponin,
Sigma-Aldrich). Blocking was carried out with PERM
buffer containing 10% goat serum for 30 minutes. Pri-
mary antibody (an equal mixture of two mouse mAbs to
two separate epitopes on p24; ADP 365 and 366, AIDS
Reagent Program, NIBSC, UK) was added at a final dilu-
tion of 1:40 and incubated for 1 hour at 4°C. Cells were
then washed three times in PERM buffer then incubated
for 30 min at 4°C with secondary antibody (goat anti-
mouse polyclonal antibody conjugated to fluorescein
isothiocyanate (FITC), Dako, Denmark). Following a
further two washes with PERM buffer and one wash
with staining buffer, the cells were fixed again with for-
maldehyde solution and analysed on a FACSCalibur
flow cytometer (Beckton Dickinson, UK) using Cellquest
software (Beckton Dickinson, UK). Uninfected, stained
cells were used as controls to set up gates for infected
cells. Samples were “blanked” by averaging the number
of events occurring in the infected gate for 6 uninfected
samples (usually averaging <0.01%) and removing this
from each test sample. Fold enhancement was deter-
mined by dividing % infected cells in the presence of
test (patient) serum by % infected cells in the presence
of control (NHS) serum. This was calculated separately
for experiments performed in the presence (C’) and
absence (HIC’) of active complement. True enhance-
ment was set at the level of 5-fold, as serum taken from
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7 uninfected individuals enhanced infection up to 3.7
fold ± 0.57 (compared to pooled control serum, NHS).
CR2 antibody-blocking assays
To assess the involvement of CR2 in C’-ADE on SupT1/
R5 cells, anti-CR2 mAbs were bound to SupT1/R5 cells
prior to standard enhancement assays. The mouse anti-
human CD21 mAb 1048 (BD Biosciences, Belgium)
recognises the short consensus repeat (SCR) 1-2 region
of CR2 and has previously been shown to block C3dg
binding to CR2 and displace HIV-1-containing immune
complexes from B cells [67]. The mouse anti-human
CD21 antibody 1F8 (Dako, Denmark), also recognising a
C3d-binding fragment of CR2, but does not inhibit C3 d
binding [68]. 1048 and 1F8 were diluted in cell culture
medium and incubated with 105 SupT1/R5 cells at
room temperature at final concentrations of 50, 10, 1,
0.1, 0.01, 0.001 and 0.0001 μg/ml. Cells were then
washed twice and used for enhancement assays as usual.
As the anti-CR2 mAbs bound to the cellular surface
might interfere with the intracellular p24 staining proce-
dure, fold enhancement was determined by RT ELISA
of the cell supernatant on day 6 following inoculation.
RT ELISA
RT activity in cell-free supernatant was determined
using the Lenti-RT Activity Assay (Cavidi Tech, Swe-
den), according to the manufacturer’s instructions.
Absorbance at 405 nm was measured in a Lucy 1 lumin-
ometer (Anthos-Labtech, UK) and analysed using Stin-
gray software (Dazdaq, East Sussex, UK).
IgG and IgM purification
IgG and IgM were purified from patient plasma using
MabTrap protein G Columns and HiTrap IgM Purifica-
tion Kit (Amersham Biosciences, UK), respectively,
according to the manufacturer’s instructions. IgG and
IgM were purified from HIV seronegative plasma (NHP)
in parallel for use as controls in the enhancement assay.
When patient IgG were serially diluted, dilutions were
performed in IgG purified from NHP (after first ensur-
ing that IgG from NHP gave a similar level of infection
to assays performed with NHS) to maintain a consistent
level of antibodies in the assay. Elution fractions were
tested for immunoglobulin content by BCA protein
assay (Thermo Fisher Scientific, UK), pooled, and recon-
stituted to the original volume of plasma used for the
purification in order to normalise results between sam-
ples. Antibody concentrations in both the purified anti-
body preparation and the original plasma source were
determined by commercial ELISA (Zeptometrix Cor-
poration, US) according to the manufacturer’s instruc-
tions. The concentration of the purified antibody was
between 5- and 9-fold less than the concentration of
antibody in the plasma. Purified antibodies were diluted
relative to physiological concentrations of the original
plasma, or used at stated concentrations.
Construction of CR2-expressing NP2/CD4/CCR5 cells
CR2 (CD21; gene accession number NM_001877) was
amplified from SupT1 cell cDNA (prepared from cellu-
lar mRNA using an Invitrogen Superscript III kit) by
polymerase chain reaction (PCR) with primers 5’-
GCGCTGATCAGCCACCATGGGCGCCGCGGGCC-3’
and 5’-GCGCTTCGAATCAGCTGGCTGGGTTGTAT-
3’. A mutant form of CR2 lacking all but 3 amino acids
(KHR) of the cytoplasmic tail was constructed by insert-
ing a stop codon after the KHR sequence [109], using
an alternative reverse primer 5’-GCGCTTCGAAT-
CATCTGTGTTTTGATATCACGTAT-3’. PCR was per-
formed using the AccuPrime Taq DNA Polymerase
High Fidelity kit (Invitrogen, UK). PCR products were
ligated into the cloning vector pCR2.1 TOPO (Invitro-
gen, UK). The CR2 and CR2ΔCT constructs were then
subcloned into the lentiviral reporter construct pCSGW
[110,111], with the eGFP-encoding gene removed, as
BamHI/Not I fragments (N.B. partial restriction digests
were necessary due to an internal BamHI site in the
CR2 coding sequence). The CR2- or CR2ΔCT-encoding
plasmids were co-transfected into subconfluent 293T
cells with the packaging and envelope plasmids
pCMVΔ8.2 and pVSV-G to produce lentiviral vectors,
as described elsewhere [111]. NP2/CD4/CCR5 cells sta-
bly expressing CR2 or CR2ΔCT were produced by lenti-
viral vector transduction, and expression of the full-
length and mutant receptors on the cell surface was
detected by flow cytometry.
Additional material
Additional file 1: Supplementary Figure 1. Patient antibody profiles.
(A) Anti-gp120 antibody levels were determined by a gp120 ELISA based
on gp120 from IIIB. Antibody levels were standardised to pooled positive
control serum from chronically-infected individuals, indicated on the
graphs by the dashed horizontal line, to allow direct comparisons
between individuals. Results shown are from sera diluted 1:100, except
pooled positive control sera, assayed at 1:1000. All seronegative samples
tested gave negative relative light unit (RLU) readings following
background subtraction. The monoclonal anti-gp120 antibody IgGb12,
when used in the same ELISA at 125 ng/ml, gave an RLU output of 1016.
(B) Anti-gp41 antibody levels were determined by a gp41 ELISA based
on the IIIB gp41. Antibody levels were standardised to pooled serum
from chronically-infected individuals, indicated on the graphs by the
upper dashed horizontal line. Results shown are from sera diluted
1:25,000. Lower dashed horizontal lines indicate seronegative samples.
The monoclonal anti-gp41 antibody 4E10 when used in the same ELISA
at 0.4 μg/ml gave an RLU output of 770.
Additional file 2: Supplementary Figure 2. The co-existence of C’-
ADE and C’-MI activity in early serum samples from an infected
individual. C’-MI, C’-ADE and neutralisation assays were carried out using
early virus (MM26.62) and sequential autologous serum samples from
MM26. Anti-gp120 antibody levels were measured in sequential serum
samples from MM26 by ELISA. (A) Anti-gp120 antibody levels in MM26
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serum, detected by binding to HIV-1 IIIB gp120 in ELISA and expressed
as RLU. (B) Neutralisation assay on NP2/CD4/R5 cells. Percentage
neutralisation is calculated relative to infection in the presence of NHS.
(C) C’-MI assay on NP2/CD4/R5 cells. Percentage inactivation is calculated
relative to infection in the presence of NHS and C’. (D) Enhancement
assay on SupT1/R5 cells. Fold enhancement is calculated relative to
infection in the presence of NHS and C’. Note that all assays were carried
out with the same sera and virus whilst the target cell and presence of
C’ differs between them.
Additional file 3: Supplementary Figure 3. C’-ADE by monoclonal
antibodies. The enhancing mAb 246-D and the neutralising mAb
IgGb12 were serially diluted in NHS then incubated with C’ or HIC’ and
virus, as per the standard enhancement assays. Fold enhancement is
calculated relative to infection in the presence of NHS and C’, as for
other enhancement assays. Results are shown for IIIB (top panels) and
patient primary isolate MM38.29 (bottom panels). White squares
represent assays conducted in the presence of HIC’; black squares, C’.
Additional file 4: Supplementary Figure 4. RT correlation and
enhancement assay time course. In addition to % cells infected, fold
enhancement was also measured using RT detected in the cell
supernatant as a surrogate marker of virus production. (A) RT output was
monitored in the cellular supernatant on days 1, 3 and 6 of
enhancement assays for viruses showing high-level (MM34.32) and low-
level (MM25.18) enhancement. Results are shown for MM25.18 virus with
day 31 serum or NHS (left) and MM34.32 virus with day 25 serum or NHS
(right). MM25.18 virus: when measured by RT output, day 31 serum
enhanced infection 5.1-fold in the presence of C’ (black triangles; 639
pg/ml RT) compared to NHS + C’ (black squares; 127 pg/ml; 8.16-fold
when measured by % cells infected, see Figure 2); whereas complement
alone (NHS + C’; black squares; 127 pg/ml RT) enhanced infection 1-fold
compared to NHS + HIC’ (white squares; 125 pg/ml RT; 2.4-fold when
measured by % cells infected, see Table 1). MM34.32 virus: when
measured by RT output, day 25 serum enhanced infection 10-fold in the
presence of C’ (black triangles; 11,798 pg/ml RT) compared to NHS + C’
(black squares; 1,183 pg/ml RT; 9-fold when measured by % cells
infected, see Figure 2); whereas complement alone (NHS + C’; black
squares; 1,183 pg/ml RT) enhanced infection 7.3-fold compared to NHS +
HIC’ (white squares; 162 pg/ml RT; 9.7-fold when measured by % cells
infected, see Table 1). (B) Fold enhancement calculated from % cells
infected by MM24.26 in the presence of 8 autologous sequential serum
samples and complement (see Figure 2, MM24) was compared with fold
enhancement attained by the same serum samples but calculated from
RT output.
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